Eli Lilly's New Drug Leads 94% of Patients to Avoid Type 2 Diabetes, But Shocking Side Effects Exposed!

On August 20, 2024, Eli Lilly and Company, the world's leading pharmaceutical company, officially announced the positive results of the SURMOUNT-1 study (176 weeks of treatment). This study explores the efficacy and safety of once-weekly injections of tilpotide for long-term weight management and delaying the progression of type 2 diabetes in obese or overweight adults with prediabetes. The results of the study showed that patients treated with tilpotide had a significantly reduced risk of developing type 2 diabetes by 94 percent compared to those who received a placebo. In addition, telpotide injection sustained weight loss in patients during treatment, with patients receiving telpotide 15mg losing an average of 22.9% of their body weight at the end of treatment, compared with only 2.1% in patients receiving placebo.

Dr. Jeff Emmick, senior vice president of product development at Eli Lilly, said: "Obesity, as a chronic disease, increases the risk of developing other complications such as type 2 diabetes for nearly 900 million adults worldwide. Tilpotide significantly reduced the risk of developing type 2 diabetes in these patients and achieved sustained weight loss over the three-year treatment period. These data further support the potential clinical benefits of long-term treatment in patients with obesity and prediabetes."

The SURMOUNT-1 study was conducted in 1,032 randomized obese or overweight adults with prediabetes and included a treatment period of 176 weeks followed by a follow-up period of 17 weeks of discontinuation (a total of 193 weeks). Preliminary results of the SURMOUNT-1 study analysis of all participants at 72 weeks have been published in the New England Journal of Medicine in 2022.

In the evaluation of key secondary endpoints, telpotide significantly reduced the risk of progression to type 2 diabetes in obese or overweight adults with prediabetes from baseline to week 176 (p<0.0001, controlling for Class 1 error). Efficacy estimate targets showed that the telpotide (combined dose) group achieved a significant effect: a 94% reduction in the risk of progressing to type 2 diabetes at week 176 compared with placebo. Treatment regimen estimate targets showed that the telpotide (combined dose) group at week 176 significantly reduced the risk of progressing to type 2 diabetes by 93% compared with placebo.

In another evaluation of key secondary endpoints, tilpotide (10mg and 15mg) achieved statistically significant (p<0.001, controlling for class 1 errors) weight loss in obese or overweight adults with prediabetes from baseline to week 176 compared with placebo. Efficacy estimate targets showed that at week 176, adult participants in the telpotide group had an average weight loss of 15.4% (5mgi), 19.9% (10mg) and 22.9% (15mg) compared with placebo (2.1%). Treatment regimen estimate targets showed that at week 176, adult participants using tilpotide had an average weight loss of 12.3% (5mgi), 18.7% (10mg), and 19.7% (15mg) compared with placebo (1.3%).

During the 17-week follow-up, patients who stopped tilpotide began to gain weight and had a slightly increased chance of progressing to type 2 diabetes. Compared with placebo, the risk of progressing to type 2 diabetes was reduced by 88% (p<0.0001, controlling for Class 1 errors).

The overall safety and tolerability of tilpotide in the 193-week study were similar to those previously reported in the 72-week SURMOUNT-1 study and other tilpotide long-term weight management studies. The most common adverse events reported were gastrointestinal related and were mostly mild to moderate in severity. The most common gastrointestinal related adverse events in patients treated with tilpotide were diarrhea, nausea, constipation, and vomiting.

Glucose-dependent insulin stimulating polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist Tilpotide binds to and activates two of the body's natural incretin receptors. GLP-1 regulates appetite and calorie intake. In preclinical models, the addition of GIP has been shown to further reduce food intake. Tilpotide reduces calorie intake by reducing appetite. In addition, tilpotide stimulates insulin secretion in a glucose-dependent manner. Tilpotide improves insulin sensitivity and lowers blood sugar levels in patients with type 2 diabetes.

The results of this study demonstrate that the use of tilpotide reduces the risk of developing type 2 diabetes in obese or overweight adults with prediabetes and can maintain weight loss over time. Detailed results will be submitted to peer-reviewed journals and published at ObesityWeek 2024, November 3-6.